[1] |
Bhat GR, Hyole RG, Li J. Head and neck cancer: Current challenges and future perspectives[J]. Adv Cancer Res, 2021, 152: 67-102.
doi: 10.1016/bs.acr.2021.05.002
pmid: 34353444
|
[2] |
Zehnder AM, Swift LA, Sundaram A, et al. Clinical features, treatment, and outcomes of cutaneous and oral squamous cell carcinoma in avian species[J]. J Am Vet Med Assoc, 2018, 252(3):309-315.
doi: 10.2460/javma.252.3.309
|
[3] |
Zhang W, Lu X, Cui PL, et al. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer[J]. Cancer Immunol Immunother, 2019, 68(1):121-130.
doi: 10.1007/s00262-018-2257-2
pmid: 30306202
|
[4] |
Klechevsky E. Functional diversity of human dendritic cells[J]. Adv Exp Med Biol, 2015, 850: 43-54.
doi: 10.1007/978-3-319-15774-0_4
pmid: 26324345
|
[5] |
Zong JB, Keskinov AA, Shurin GV, et al. Tumor-derived factors modulating dendritic cell function[J]. Cancer Immunol Immunother, 2016, 65(7):821-833.
doi: 10.1007/s00262-016-1820-y
pmid: 26984847
|
[6] |
Schuler PJ, Harasymczuk M, Visus C, et al. Phase Ⅰ dendritic cell p53 peptide vaccine for head and neck cancer[J]. Clin Cancer Res, 2014, 20(9):2433-2444.
doi: 10.1158/1078-0432.CCR-13-2617
|
[7] |
Bagheri V, Abbaszadegan MR, Memar B, et al. Induction of T cell-mediated immune response by dendritic cells pulsed with mRNA of sphere-forming cells isolated from patients with gastric cancer[J]. Life Sci, 2019, 219: 136-143.
doi: S0024-3205(19)30016-5
pmid: 30641083
|
[8] |
Wang Z, Hu Q, Han W, et al. Effect of dendritic cell vaccine against a tongue squamous cell cancer cell line (Tca8113) in vivo and in vitro[J]. Int J Oral Maxillofac Surg, 2006, 35(6):544-550.
doi: 10.1016/j.ijom.2005.11.004
|
[9] |
Ziogas AC, Gavalas NG, Tsiatas M, et al. VEGF directly suppre-sses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2[J]. Int J Cancer, 2012, 130(4):857-864.
doi: 10.1002/ijc.v130.4
|
[10] |
Kandalaft LE, Motz GT, Busch J, et al. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin[M/OL]//Dranoff G. Cancer immunology and immunotherapy. current topics in microbiology and immunology. Berlin, Heidelber: Springer, 2010:129-148[2022-09-08]. https://doi.org/10.1007/82_2010_95.
|
[11] |
Hargadon KM, Bishop JD, Brandt JP, et al. Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells[J]. Immunol Cell Biol, 2016, 94(1):24-38.
doi: 10.1038/icb.2015.58
pmid: 26010746
|
[12] |
Mou YB, Xie H, Huang XF, et al. Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine[J]. Oncol Lett, 2013, 6(6):1799-1803.
pmid: 24260079
|
[13] |
Mellor AL, Lemos H, Huang L. Indoleamine 2, 3-dioxygenase and tolerance:Where are we now?[J]. Front Immunol, 2017, 8: 1360.
doi: 10.3389/fimmu.2017.01360
|
[14] |
Chadburn A. The spleen:Anatomy and anatomical function[J]. Semin Hematol, 2000, 37(1 Suppl 1):13-21.
pmid: 10676919
|
[15] |
Dudek AM, Martin S, Garg AD, et al. Immature, semi-mature, and fully mature dendritic cells: Toward a DC-cancer cells interface that augments anticancer immunity[J]. Front Immunol, 2013, 4: 438.
doi: 10.3389/fimmu.2013.00438
pmid: 24376443
|
[16] |
Motta JM, Rumjanek VM. Sensitivity of dendritic cells to microenvironment signals[J]. J Immunol Res, 2016, 2016: 4753607.
|
[17] |
Han ZY, Dong YC, Lu JZ, et al. Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: Mechanism and application[J]. Am J Cancer Res, 2021, 11(8):3777-3793.
pmid: 34522449
|
[18] |
Ninomiya S, Narala N, Huye L, et al. Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs[J]. Blood, 2015, 125(25):3905-3916.
doi: 10.1182/blood-2015-01-621474
|
[19] |
Lu SH, Concha-Benavente F, Shayan G, et al. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV + status in head and neck cancer[J]. Oral Oncol, 2018, 78: 186-193.
doi: 10.1016/j.oraloncology.2018.01.019
|
[20] |
Platten M, von Knebel Doeberitz N, Oezen I, et al. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors[J]. Front Immunol, 2015, 5: 673.
|
[21] |
Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: Recent progress and potential biomarkers[J]. Exp Mol Med, 2018, 50(12):1-11.
doi: 10.1038/s12276-018-0191-1
pmid: 30546008
|
[22] |
Lin YM, Sung WW, Hsieh MJ, et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma[J]. PLoS One, 2015, 10(11):e0142656.
doi: 10.1371/journal.pone.0142656
|
[23] |
Marti LC, Pavon L, Severino P, et al. Vascular endothelial growth factor-A enhances indoleamine 2, 3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation[J]. Mem Inst Oswaldo Cruz, 2014, 109(1):70-79.
doi: 10.1590/0074-0276130252
|
[24] |
Harden JL, Egilmez NK. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity[J]. Immunol Invest, 2012, 41(6/7):738-764.
doi: 10.3109/08820139.2012.676122
|
[25] |
Meng XJ, Liu YL, Zhang JJ, et al. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges[J]. Cancer Lett, 2017, 405: 29-37.
doi: S0304-3835(17)30415-9
pmid: 28688973
|
[26] |
Pei QS, Pan JM, Zhu H, et al. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells[J]. Int Immunopharmacol, 2014, 19(1):10-16.
doi: 10.1016/j.intimp.2013.12.022
pmid: 24389382
|
[27] |
Selvan SR, Dowling JP, Kelly WK, et al. Indoleamine 2, 3-dioxygenase (IDO):Biology and target in cancer immunotherapies[J]. Curr Cancer Drug Targets, 2016, 16(9):755-764.
doi: 10.2174/1568009615666151030102250
|